More recently, an open-label early phase 1 trial of “D + Q” for AD (SToMP-AD) reported that intermittent senolytic administration decreases tau protein accumulation and neuro-inflammation, preserves neuronal and synaptic density, partly restores cerebral blood flow and reduces ventricular enlargement [147]. Here, MAPT is linked to Alzheimer disease.